Problematic End Points in a Trial of Topical Fluorouracil, 5%, for Chemoprevention of Keratinocyte Carcinoma-Reply

Journal article

Peer reviewed

Martin A Weinstock, Robert A Lew, Fiona M Shaw, Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial (VAKCC) Group and Jonette E Keri

JAMA dermatology (Chicago, Ill.), Vol.154(7), pp.851-852

2018-07-01

PMID: 29898230

Abstract

Carcinoma, Squamous Cell

Chemoprevention

Fluorouracil

Humans

Keratinocytes

4 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.158 Dermatology - General; 1.158.201 Melanoma
Web Of Science research areas: Dermatology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Problematic End Points in a Trial of Topical Fluorouracil, 5%, for Chemoprevention of Keratinocyte Carcinoma-Reply
Creators: Martin A Weinstock - Veterans Health Administration
Robert A Lew - Boston Cooperative Studies Program Coordinating Center, Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC), Boston
Fiona M Shaw - Veterans Health Administration
Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial (VAKCC) Group
Jonette E Keri - UMMG Dept of Dermatology & Cutaneous Surgery
Publication Details: JAMA dermatology (Chicago, Ill.), Vol.154(7), pp.851-852
Academic Unit: Miller School of Medicine; UMMG Dept of Dermatology & Cutaneous Surgery
Language: English
Resource Type: Journal article
PMID: 29898230
Record Identifier: 991031723368302976